NCT04544943View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

September 21, 2022

Study Completion Date

September 21, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

BioLexa- Cohort 1

Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects

DRUG

BioLexa- Cohort 2

Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients

DRUG

Placebo

Twice daily (BID) application of placebo for 14 days

DRUG

Gentamicin

Twice daily (BID) application of Gentamicin for 14 days

Trial Locations (1)

2289

Novatrials, Kotara

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Hoth Therapeutics, Inc.

OTHER

NCT04544943 - Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter